

**DRUG PRIOR AUTHORIZATION COMMITTEE MEETING**  
**March 16, 2017**  
**La Charette/Nightingale Rooms, 1101 Riverside Drive, Jefferson City, MO**

**Committee Members Present**

Conrad Balcer, D.O  
Patrick Bryant, Pharm D  
Jennifer Kemp-Oestrich, Pharm D  
Laura Kingsley, Pharm D  
Morgan Sperry, Pharm D- \* Non-voting member this mtg.  
Laine Young-Walker, M.D.

**MO HealthNet Staff Present:**

Stephen Calloway, R.Ph, Director of Pharmacy  
Mark Roaseau, R.Ph, Clinical Pharmacist  
Jenna McTeer, RN, Clinical Management  
Angela Wilson, Manager, Band I  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Mitch Ruth, Fiscal Unit Manager  
Elizabeth Short, Medicaid Specialist  
Dr. Timothy Kling, MD, Assistant Medical Director  
Lisa E. Smith, Medicaid Specialist

**Contractors in Attendance:**

Kathleen Wilbers, Pharm D, Conduent  
Joshua Moore, Pharm D, Conduent  
Rick Pope, Pharm D, Magellan

**Others Attending:**

Anne McNamara, Otonomy	Tom Leizia, Mylan
Evan Rushing, Alkermes	Chris Stanfield, Spernus
Mary Kelly, Sunovion	Mike Lafond, Abbvie
Brian Strickland, Giliad	Steve Naert, Lilly
Matt Bradley, Novartis	Lee Stout, Chiesi
Brian Rose, Merck	Don Kempir, Novo Nordisk
Marla Wiedermann, Nov- Nordisk	Aaron Shaw, Boehringer Ingelheim
John Bullard, Amgen	Mike Donze, Boehringer Ingelheim
Scott Jones, Astra Zeneca	

<b>Welcome, Introductions and Opening Remarks</b>	Conrad Balcer, D.O., Acting Committee Chairman, called the meeting to order. Stephen Calloway introduced himself and started the introductions and opening remarks.
<b>Minutes Approval</b>	Minutes of the December 15, 2016 Drug PA meeting were reviewed and approved. Conrad Balcer, D.O. motioned and Pat Bryant seconded the motion. (See Roll Call Vote)
<b>Pharmacy Program/Budget Update</b>	Stephen Calloway presented a brief slideshow. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking.
<b>DUR Report</b>	Stephen Calloway stated all PDL Renewals from the December 2016 Drug PA Meeting were ratified at the January 2017 DUR Board Meeting.
<b>Old Business</b>	
<b>Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule included the September/October 2016 PDL classes that were implemented January 2017. Schedules may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf</a>
<b>Hepatitis C Therapy Criteria</b>	Mr. Calloway led a discussion and solicited input from the Committee regarding MHD requirement for submission of participant alcohol and drug testing information/results as part of the Hepatitis C (HCV) therapy request.
<b>New Business</b>	
<b>New Drug Review</b>	<p>Stephen Calloway reviewed the new drug products that were identified for the quarter October, November, December 2016 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>• <b>Discussion</b> – A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending.</li> <li>• <b>Decision</b> – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)</li> </ul>
<b>Clinical Edits (There were no Clinical Edits to review)</b>	
<b>Preferred Drug List (PDL)</b>	
<b>Benzoyl Peroxide/Clindamycin Topical Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there were changes for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta – Adrenergic Agents: Long Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No Comments Entered.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta – Adrenergic Agents: Nebulized</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta – Adrenergic Agents: Short Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated no changes as recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>COPD Anticholinergics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Cough &amp; Cold Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated no changes as recommended for this class. Preferred and non-preferred agents are listed in a separate appendix.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Herpes (Oral) Antivirals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated no changes as recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Inhaled Antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated no changes as recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Inhaled Corticosteroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Intranasal Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Leukotriene Modifiers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Low Sedating 2<sup>nd</sup> Generation Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Low Sedating 2<sup>nd</sup> Generation Antihistamine/Decongestant Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Ophthalmic Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Mast Cell Stabilizers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic NSAIDS</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Prostaglandin Agonists</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ophthalmic Fluoroquinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Oral Agents for Psoriasis</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated this is a new PDL therapeutic class as proposed in December 2016.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Oral Antifungals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Otic Fluoroquinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Pancreatic Enzymes</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Self-Injectable Epinephrine Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Agents for Actinic Keratosis</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated this is a new PDL therapeutic class as proposed in December 2016.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Agents for Psoriasis</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Androgenic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Antifungals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Antiparasitics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Antivirals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Immunomodulators (Atopic Dermatitis)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Retinoids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Steroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>

<b>Ulcerative Colitis Agents - Oral</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ulcerative Colitis Agents - Rectal</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Mr. Calloway stated there are no changes recommended for this class.</li> <li>• <b>Public Hearing</b> – No comments were entered.</li> <li>• <b>Decision</b> – The Committee voted to accept this PDL edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a>

<b>Conduent Update</b>	Joshua Moore, Pharm D, reviewed clinical edits, utilization data and trends for ADHD. Also, spoke about the different reasons for denials.
<b>Program Utilization: Top 25 Drugs Summary</b>	Joshua Moore, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 <sup>nd</sup> , 3 <sup>rd</sup> , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Call Center Statistics/ CyberAccess Reports</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Joshua Moore reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess.
<b>Adjourn</b>	The meeting was adjourned. The next meeting of the Drug Prior Authorization Committee is scheduled for Thursday, <b>June 15, 2017</b> at the <b>Missouri Coalition For Community Behavior, CEO Rm-Lower Level, 221 Metro Drive, Jefferson City, MO</b> . Attendees were advised to check the <a href="#">calendar of events</a> on the MHD website for meeting location changes over the next few months. (See attached roll call)

**Roll Call Votes – March 16, 2017**

<u>Member</u>	Minutes	New Drugs Review	Benzoyl Peroxide/Clindamycin Topical Agents	Beta - Adrenergic Agents: Long Acting	Beta - Adrenergic Agents: Nebulized	Beta - Adrenergic Agents: Short Acting	COPD Anticholinergics
Conrad Balcer, D.O.	YM	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	YS	YM	YM	YS	YS	YM	YS
Laura Kingsley, Pharm D	Y	Y	Y	Y	Y	Y	YM
Laine Young-Walker, M.D.	Y	Y	Y	Y	Y	YS	Y
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	Y	YS	YS	YM	YM	Y	Y

**Roll Call Votes – March 16, 2017**

<u>Member</u>	Cough & Cold Agents	Herpes (Oral) Antivirals	Inhaled Antibiotics	Inhaled Corticosteroid	Intranasal Antihistamines	Intranasal Corticosteroids	Leukotriene Modifiers
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	YM	YM	YM	Y	YS	Y	Y
Laura Kingsley, Pharm D	Y	Y	Y	Y	Y	YS	YS
Laine Young-Walker, M.D.	YS	YS	YS	YM	YM	Y	Y
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	Y	Y	Y	YS	Y	YM	YM



**Roll Call Votes – March 16, 2017**

<u>Member</u>	Low Sedating Antihistamines	Low Sedating Antihistamines /Decongestant Combinations	Ophthalmic Antihistamines	Ophthalmic Mast Cell Stabilizers	Ophthalmic NSAIDS	Ophthalmic Prostaglandin Agonists	Ophthalmic Quinolones
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	YS	Y	YS	YM	Y	Y	YM
Laura Kingsley, Pharm D	Y	Y	Y	YS	Y	YS	YS
Laine Young-Walker, M.D.	YM	YM	YM	Y	YM	Y	Y
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	Y	YS	Y	Y	YS	YM	Y

**Roll Call Votes – March 16, 2017**

<u>Member</u>	Oral Agents for Psoriasis	Oral Antifungals	Otic Quinolones	Pancreatic Enzymes	Self - Injectable Equipment Agents	Topical Agents for Actinic Keratosis	Topical Agents for Psoriasis
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	YS	Y	YS	YM	Y	Y	YM
Laura Kingsley, Pharm D	Y	Y	Y	YS	Y	YS	YS
Laine Young-Walker, M.D.	YM	YM	YM	Y	YM	Y	Y
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	Y	YS	Y	Y	YS	YM	Y

**Roll Call Votes – March 16, 2017**

<u>Member</u>	Topical Androgenic Agents	Topical Antifungals	Topical Antiparasitics	Topical Antivirals	Topical Immunomodulators (Atopic Dermatitis)	Topical Immunomodulators (Atopic Dermatitis)	Topical Steroids
Conrad Balcer, D.O.	Y	Y	Y	Y	Y	Y	Y
Pat Bryant, Pharm D	Y	Y	Y	YS	YM	YS	YS
Laura Kingsley, Pharm D	YS	Y	YS	YM	Y	YM	Y
Laine Young-Walker, M.D.	Y	YM	YM	Y	Y	Y	YM
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	YM	YS	Y	Y	YS	Y	Y

**Roll Call Votes – March 16, 2017**

<u>Member</u>	Ulcerative Colitis Agents - Oral	Ulcerative Colitis Agents - Rectal	Motion To Close				
Conrad Balcer, D.O.	Y	Y	Y				
Pat Bryant, Pharm D	YM	YM	YS				
Laura Kingsley, Pharm D	YS	Y	Y				
Laine Young-Walker, M.D.	Y	YS	Y				
Morgan Sperry, Pharm D							
Jennifer Kemp-Oestrich, Pharm D	Y	Y	YM				